Study identifier:D1520C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single Centre, Open-Label Study to Assess the Pharmacokinetics of both AZD9056 (Steady State) and Simvastatin (Single Dose) when Co-Administered in Healthy Volunteers
Healthy Volunteers
Phase 1
Yes
simvastatin, AZD9056 + simvastatin
All
12
Interventional
18 Years - 55 Years
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to assess the pharmacokinetics of both AZD9056 (steady state) and simvastatin (single dose) when co-administered in healthy volunteers
Location
Location
Berlin, Germany
Arms | Assigned Interventions |
---|---|
Experimental: Period 1 simvastatin | Drug: simvastatin One single dose of 40mg Other Name: Zocor |
Experimental: Period 2 simvastatin + AZD9056 | Drug: AZD9056 + simvastatin AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7 Other Name: Zocor |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.